Osteoporosis | Disease Landscape & Forecast | G7 | 2018
Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures, in turn, place a considerable burden on public health systems. The osteoporosis therapy market is maturing, and treatment of the disease is associated with significant unmet need, particularly for therapies that are safer and more efficacious, especially those that can reduce the risk of nonvertebral fractures (e.g., hip fractures). The launch of several key therapies will lead to significant market changes over the 2017-2027 forecast period. In particular, Amgen/UCB/Astellas BioPharma’s romosozumab and Radius Health’s abaloparatide—in both subcutaneous(SC) and transdermal (TD) administration—will energize the market.
Questions Answered:
- Novel agents—Radius Health’s abaloparatide SC and TD and Amgen/UCB/Astellas BioPharma’s romosozumab—are in late-stage development, registered, or recently launched for the treatment of osteoporosis. What do interviewed thought leaders say about the advantages and disadvantages of each therapy? How do they anticipate using them in the osteoporosis treatment algorithm? Which agents in the current market are most vulnerable to being replaced by these novel therapies, and which ones will constrain uptake of the new drugs?
- The bisphosphonate drug class (e.g., alendronate, risedronate, ibandronate, zoledronate) is the dominant drug class for the treatment of osteoporosis but is associated with adverse effects, including osteonecrosis of the jaw and an elevated risk of atypical femoral fractures. How much impact will this association have on osteoporosis and osteopenia drug-treatment rates? To what extent will this association adversely affect bisphosphonate sales?
- Teriparatide and denosumab hold a sizable share of the market. How will the loss of patent protection affect their market share? What effect will the launch of novel agents have on their patient share?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts.
Epidemiology: Osteopenia, osteoporosis, and total prevalent cases of FRAX high-risk.
Population segments in market forecast: Osteoporosis.
Emerging therapies: Registered: 1 drug; Phase II: 1 drug. Coverage of select preclinical and Phase I products.
Key drugs: Denosumab, teriparatide, abaloparatide SC, abaloparatide TD, alendronate, romosozumab, raloxifene
